GLP1R and chronic obstructive pulmonary disease: Research conducted on an innovative experimental animal model of lung diseases (a combination of a model of mice with asthma induced by exacerbation of the underlying disease through administration of ovalbumins and mice manifesting COPD during an exacerbation episode caused by lipopolysaccharides) undergoing Ex-4 therapy resulted in a significant reduction in the mortality of mice with COPD through the induction of bronchial relaxation, not only by relaxing smooth muscles through GLP-1 but also by myorelaxation of the muscle layer in the vascular bed [52].